➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Merck
Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: April 21, 2021

DrugPatentWatch Database Preview

CEFUROXIME SODIUM Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cefuroxime Sodium, and what generic alternatives are available?

Cefuroxime Sodium is a drug marketed by Acs Dobfar Spa, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira Inc, Teva Pharms, Watson Labs Inc, and Samson Medcl. and is included in fourteen NDAs.

The generic ingredient in CEFUROXIME SODIUM is cefuroxime sodium. There are sixty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cefuroxime Sodium

A generic version of CEFUROXIME SODIUM was approved as cefuroxime sodium by ACS DOBFAR SPA on May 30th, 1997.

  Start Trial

Drug patent expirations by year for CEFUROXIME SODIUM
Recent Clinical Trials for CEFUROXIME SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital Universitari Vall d'Hebron Research InstitutePhase 4
University Hospital, Basel, SwitzerlandPhase 4
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2/Phase 3

See all CEFUROXIME SODIUM clinical trials

Pharmacology for CEFUROXIME SODIUM

US Patents and Regulatory Information for CEFUROXIME SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acs Dobfar Spa CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INJECTION 064125-002 May 30, 1997 AP RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 064192-002 Apr 16, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira Inc CEFUROXIME SODIUM cefuroxime sodium INJECTABLE;INJECTION 065483-002 Oct 15, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKinsey
McKesson
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.